Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIDE: Platinum reintroduction with gemcitabine + cisplatin after GCD + durvalumab in biliary tract cancer
jRCTs031250085Phase 2Recruiting
- Start
- May 2025
- Modality
- Small Molecules, PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab, gemcitabine and cisplatin in biliary cancer. Primary endpoint: Survival rate at 6 months. Started May 2025; status: recruiting.
02
Drugs
durvalumabgemcitabinecisplatin
03
Conditions
biliary cancer
Beyond the preview
Go deeper on jRCTs031250085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031250085.